Protagonist Therapeutics (PTGX) Payables (2017 - 2025)
Historic Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $22.9 million.
- Protagonist Therapeutics' Payables rose 1026.57% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 1026.57%. This contributed to the annual value of $23.7 million for FY2024, which is 2239.38% up from last year.
- Latest data reveals that Protagonist Therapeutics reported Payables of $22.9 million as of Q3 2025, which was up 1026.57% from $15.4 million recorded in Q2 2025.
- Protagonist Therapeutics' 5-year Payables high stood at $37.7 million for Q4 2021, and its period low was $11.8 million during Q1 2025.
- Over the past 5 years, Protagonist Therapeutics' median Payables value was $20.7 million (recorded in 2024), while the average stood at $23.1 million.
- In the last 5 years, Protagonist Therapeutics' Payables surged by 11304.94% in 2021 and then plummeted by 4954.37% in 2023.
- Protagonist Therapeutics' Payables (Quarter) stood at $37.7 million in 2021, then tumbled by 33.83% to $25.0 million in 2022, then dropped by 22.43% to $19.4 million in 2023, then grew by 22.39% to $23.7 million in 2024, then decreased by 3.48% to $22.9 million in 2025.
- Its Payables stands at $22.9 million for Q3 2025, versus $15.4 million for Q2 2025 and $11.8 million for Q1 2025.